vs
Side-by-side financial comparison of Commercial Bancgroup, Inc. (CBK) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $20.4M, roughly 1.1× Sight Sciences, Inc.). Commercial Bancgroup, Inc. runs the higher net margin — 41.3% vs -20.4%, a 61.7% gap on every dollar of revenue.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CBK vs SGHT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $20.4M |
| Net Profit | $9.5M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | — | -18.0% |
| Net Margin | 41.3% | -20.4% |
| Revenue YoY | — | 6.9% |
| Net Profit YoY | 9.7% | 64.9% |
| EPS (diluted) | $0.69 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | $20.4M | ||
| Q3 25 | $22.8M | $19.9M | ||
| Q2 25 | — | $19.6M | ||
| Q1 25 | — | $17.5M | ||
| Q4 24 | — | $19.1M | ||
| Q3 24 | — | $20.2M | ||
| Q2 24 | — | $21.4M |
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | $-4.2M | ||
| Q3 25 | $9.5M | $-8.2M | ||
| Q2 25 | — | $-11.9M | ||
| Q1 25 | — | $-14.2M | ||
| Q4 24 | — | $-11.8M | ||
| Q3 24 | — | $-11.1M | ||
| Q2 24 | — | $-12.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | -18.0% | ||
| Q3 25 | 53.8% | -39.7% | ||
| Q2 25 | — | -59.6% | ||
| Q1 25 | — | -79.2% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | — | -55.7% | ||
| Q2 24 | — | -59.2% |
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | -20.4% | ||
| Q3 25 | 41.4% | -41.0% | ||
| Q2 25 | — | -61.0% | ||
| Q1 25 | — | -80.8% | ||
| Q4 24 | — | -62.1% | ||
| Q3 24 | — | -54.9% | ||
| Q2 24 | — | -57.7% |
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | $-0.07 | ||
| Q3 25 | $0.77 | $-0.16 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.28 | ||
| Q4 24 | — | $-0.23 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $92.0M |
| Total DebtLower is stronger | $118.2M | $42.4M |
| Stockholders' EquityBook value | — | $63.9M |
| Total Assets | $2.3B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $92.0M | ||
| Q3 25 | $154.8M | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M |
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | $42.4M | ||
| Q3 25 | $100.1M | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $63.9M | ||
| Q3 25 | $245.2M | $64.3M | ||
| Q2 25 | — | $70.0M | ||
| Q1 25 | — | $77.6M | ||
| Q4 24 | — | $87.5M | ||
| Q3 24 | — | $95.0M | ||
| Q2 24 | — | $101.6M |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $115.3M | ||
| Q3 25 | $2.2B | $116.3M | ||
| Q2 25 | — | $122.0M | ||
| Q1 25 | — | $129.7M | ||
| Q4 24 | — | $142.8M | ||
| Q3 24 | — | $143.6M | ||
| Q2 24 | — | $149.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | 0.41× | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-1.8M | ||
| Q3 25 | $28.0M | $-8.7M | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | — | $-11.6M | ||
| Q4 24 | — | $-3.5M | ||
| Q3 24 | — | $362.0K | ||
| Q2 24 | — | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-2.0M | ||
| Q3 25 | $26.5M | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | -9.7% | ||
| Q3 25 | 115.8% | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.8% | ||
| Q3 25 | 6.7% | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
